Research Options:

Week of Expected Pricing 11/4/2021
Company Name MDXHEALTH SA
Proposed Ticker MDXH
CUSIP 5.83E+106
Business Description A commercial-stage precision diagnostics company committed to providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care. Our novel prostate cancer genomic testing solutions, SelectMDx and ConfirmMDx, provide physicians with a clear clinical pathway to accurately identify clinically significant prostate cancer while minimizing the use of invasive procedures that are prone to complications.
Lead Underwriter Oppenheimer & Co. Inc., Piper Sandler & Co
Co-Managers BTIG, LLC, KBC Securities USA LLC
Initial Shares 37,50,000
Revised Initial Shares N/A
Initial Price $12.00-$12.00
Revised Price N/A
Final Price $12.00
Final Ticker MDXH

 

 

   
  © 2024 ICE Data Services. All rights reserved.